3CPLro-IN-2 is a potent, orally bioavailable inhibitor of the SARS-CoV-2 3CL protease (3CLpro), with an IC50 of 1.55 µM. This essential viral enzyme is a key drug target for COVID-19, making this compound a valuable tool for antiviral research in both in vitro and in vivo studies.